Suzanne T. Ildstad, M.D.

Director, Institute for Cellular Therapeutics


Research Interests

Characterization of the Facilitating Cells
Facilitating cells enable the long-term, durable engraftment of hematopoietic stem cells across genetic barriers. How do these unique cells function, and what is their ontogeny?

The Sensitized State

Sensitized recipients are more prone to bone marrow and solid organ graft rejection. Mixed chimerism may reverse the immunologic memory and establish donor specific tolerance. How can we overcome immunologic memory barrier in sensitized recipient for successful bone marrow transplantation?

Nonmyeloablative Conditioning for bone marrow transplantation
We are working to develop nonmyeloablative (and therefore, less toxic) conditioning strategies for the establishment of mixed chimerism. What are the cells in the recipient microenvironment, that prevent engraftment, and how can we best target these cells and the pathways to suppress the function of these cells?

Diabetes and Autoimmunity
Through the use of a non-obese diabetic mouse model, we are working to establish mixed chimerism for the treatment of autoimmune diseases.

Entrepreneurial Leave
Suzanne Ildstad has been granted entrepreneurial leave (E-Leave) by the University of Louisville to join Regenerex, Inc., a biotechnology allogeneic cell therapy company, which she founded.  Dr. Ildstad remains the Director of The Institute for Cellular Therapeutics, the Jewish Hospital Distinguished Professor of Transplantation and a Distinguished University Scholar.  This leave will allow her to make this transformative therapy widely available to patients.